

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 September 2025 (12.09.2025)



(10) International Publication Number
WO 2025/186213 A1

(51) International Patent Classification:

A61K 31/4745 (2006.01) A61P 35/00 (2006.01)
A61K 45/06 (2006.01) A61K 47/68 (2017.01)
A61K 47/50 (2017.01)

(21) International Application Number:

PCT/EP2025/055765

(22) International Filing Date:

04 March 2025 (04.03.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

24161256.3 04 March 2024 (04.03.2024) EP
24201896.8 23 September 2024 (23.09.2024) EP

(71) Applicant: **DEBIOPHARM INTERNATIONAL S.A.**
[CH/CH]; Forum "après-demain", Chemin Messidor 5-7,
1006 Lausanne (CH).

(72) Inventors: **VASLIN CHESSEX, Anne**; c/o Debiopharm
International S.A., Forum "après-demain", Chemin Mes-
sidor 5-7, 1006 Lausanne (CH). **PIGGOTT, Luke**; c/
o Debiopharm International S.A., Forum "après-demain",
Chemin Messidor 5-7, 1006 Lausanne (CH). **RODRIGO**

IMEDIO, Esteban; c/o Debiopharm International S.A., Fo-
rum "après-demain", Chemin Messidor 5-7, 1006 Lausanne
(CH).

(74) Agent: **HOFFMANN EITLE PATENT- UND
RECHTSANWÄLTE PARTMBB**; Arabellastraße 30,
81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: COMBINATION OF A WEE1 INHIBITOR AND A TOPOISOMERASE 1 INHIBITOR




Figure 1

(57) Abstract: Methods of treating cancer using a combination of a WEE1 inhibitor and a topoisomerase 1 inhibitor are provided.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*